Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
- 1 December 2003
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (23), 4444-4454
- https://doi.org/10.1200/jco.2003.07.200
Abstract
Purpose: In 1999, investigators reported promising results of a phase II study of thalidomide in patients with resistant multiple myeloma (MM). Since then, various trials of thalidomide alone and in combination with other agents have been tested in patients with resistant and, more recently, untreated MM. In addition, preliminary results of phase I studies of the immunomodulatory derivatives (IMiDs) of thalidomide have been recently reported.Keywords
This publication has 63 references indexed in Scilit:
- Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasoneSeminars in Oncology, 2003
- Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasoneSeminars in Oncology, 2003
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple MyelomaMayo Clinic Proceedings, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984